CDH2 and prostate cancer: The increase of miR-139–5p greatly inhibits the expression of SOX5 in prostate cancer cells, down-regulates TWIST, and reduces the expression of N-cadherin and vimentin, thereby inhibiting the EMT process and thus inhibiting the cell proliferation and cell migration of prostate cancer cells (57).